Center-Authored Papers

Filters: Author is Zolla-Pazner, Susan  [Clear All Filters]
2010
Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self SG, Williams C, Gorny MK, Zolla-Pazner S.  2010.  Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.. PloS one. 5(4):e10254. Abstract
2012
Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam MS, Evans DT, Montefiori DC, Karnasuta C, Sutthent R et al..  2012.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.. The New England journal of medicine. 366(14):1275-86. Abstract
Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X et al..  2012.  The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120.. AIDS research and human retroviruses. 28(11):1444-57. Abstract
2013
Zolla-Pazner S, Decamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E et al..  2013.  Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.. PloS one. 8(1):e53629. Abstract
Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L et al..  2013.  Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial.. PloS one. 8(9):e75665. Abstract
2014
Zolla-Pazner S, DeCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA et al..  2014.  Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection.. PloS one. 9(2):e87572. Abstract
DeCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H et al..  2014.  Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies.. Journal of virology. 88(5):2489-507. Abstract
Yates NL, Liao H-X, Fong Y, DeCamp A, Vandergrift NA, Williams WT, Alam MS, Ferrari G, Yang Z-Y, Seaton KE et al..  2014.  Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination.. Science translational medicine. 6(228):228ra39. Abstract
Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH et al..  2014.  Analysis of HLAA*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.. Journal of virology. Abstract
Zolla-Pazner S, Edlefsen PT, Rolland M, Kong X-P, DeCamp A, Gottardo R, Williams C, Tovanabutra S, Sharpe-Cohen S, Mullins JI et al..  2014.  Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses.. EBioMedicine. 1(1):37-45. Abstract
2015
Prentice HA, Tomaras GD, Geraghty DE, Apps R, Fong Y, Ehrenberg PK, Rolland M, Kijak GH, Krebs SJ, Nelson W et al..  2015.  HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.. Science translational medicine. 7(296):296ra112. Abstract
2016
Zolla-Pazner S, Cohen SS, Boyd D, Kong X-P, Seaman M, Nussenzweig M, Klein F, Overbaugh J, Totrov M.  2016.  Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors that Affect Neutralization Sensitivity.. Journal of virology. 90(2):636-649. Abstract